Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT1002 in Patients Undergoing PCI Due to ACS With NSTEMI
NCT04723186Phase 2Terminated
- Sponsor
- Shaanxi Micot Technology Co., Ltd.
- Start
- Dec 2020
- Primary completion
- Aug 2023
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MT1002 in acute coronary syndrome (ACS), Non-ST-segment elevation myocardial infarction (NSTEMI), sponsored by Shaanxi Micot Technology Co., Ltd.. Started Dec 2020; status: terminated.
02
Drugs
MT1002
03
Conditions
acute coronary syndrome (ACS)Non-ST-segment elevation myocardial infarction (NSTEMI)
Beyond the preview
Go deeper on NCT04723186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04723186.